Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) have been given a consensus recommendation of “Moderate Buy” by the six research firms that are presently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and four have given a buy recommendation to the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $37.3333.

Several research analysts recently weighed in on the stock. UBS Group boosted their price objective on shares of Nanobiotix from $3.50 to $30.00 and gave the stock a “neutral” rating in a research report on Friday, May 1st. Weiss Ratings reiterated a “sell (d-)” rating on shares of Nanobiotix in a research report on Tuesday, April 21st. HC Wainwright reissued a “buy” rating on shares of Nanobiotix in a research note on Monday, May 18th. Guggenheim boosted their target price on Nanobiotix from $26.00 to $36.00 and gave the stock a “buy” rating in a research report on Thursday, April 2nd. Finally, Leerink Partners upped their price target on Nanobiotix from $37.00 to $46.00 and gave the company an “outperform” rating in a research note on Thursday, June 4th.

Institutional Trading of Nanobiotix

Several institutional investors and hedge funds have recently added to or reduced their stakes in NBTX. Millennium Management LLC acquired a new position in Nanobiotix during the 4th quarter valued at about $390,000. Marshall Wace LLP acquired a new stake in shares of Nanobiotix during the 4th quarter worth approximately $220,000. Finally, Royal Bank of Canada raised its stake in shares of Nanobiotix by 2,000.0% during the fourth quarter. Royal Bank of Canada now owns 2,625 shares of the company’s stock worth $61,000 after buying an additional 2,500 shares during the last quarter. 38.81% of the stock is owned by institutional investors.

Nanobiotix Price Performance

NBTX opened at $41.64 on Wednesday. Nanobiotix has a one year low of $4.93 and a one year high of $57.14. The company’s 50 day simple moving average is $39.95 and its 200-day simple moving average is $31.92.

Nanobiotix Company Profile

Nanobiotix is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the development of novel nanopharmaceuticals to improve cancer treatment. The company’s lead product, NBTXR3, is a first-in-class radioenhancer composed of hafnium oxide nanoparticles designed to amplify the effect of radiotherapy on tumor cells while sparing surrounding healthy tissue. Nanobiotix has established clinical programs across multiple cancer indications, including soft tissue sarcoma, head and neck cancer, and hepatocellular carcinoma.

Since its inception, Nanobiotix has advanced NBTXR3 through pivotal trials and secured CE Mark approval in Europe for the treatment of soft tissue sarcoma.